Plus Therapeutics (PSTV) Cash from Operations (2010 - 2026)
Plus Therapeutics (PSTV) reported Cash from Operations of 6238000.0 for Q1 2026, down 1.07% year-over-year from 6305426.79 in Q1 2025, and up 0.59% quarter-over-quarter from 6275000.0 in Q4 2025.
Plus Therapeutics (PSTV) Cash from Operations (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 17 years of Cash from Operations data on file, last reported at 6238000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 6238000.0, down 1.07% year-over-year; the trailing twelve-month figure through Mar 2026 was 20841000.0 (down 70.65% YoY), and the FY2025 annual result was 20775000.0, down 96.84% from the prior year.
- Cash from Operations climbed to 6238000.0 in Q1 2026 per PSTV's latest filing, from 6275000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 1150000.0 in Q2 2024 and troughed at 6275000.0 in Q4 2025.
- A 5-year average of 3728823.53 and a median of 3680000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations surged 58.6% in 2024, then tumbled 418.17% in 2025.
- A 5-year view of Cash from Operations shows it stood at 2234000.0 in 2022, then climbed by 15.8% to 1881000.0 in 2023, then jumped by 35.62% to 1211000.0 in 2024, then plunged by 418.17% to 6275000.0 in 2025, then advanced by 0.59% to 6238000.0 in 2026.
- Business Quant data shows PSTV's Cash from Operations at 6238000.0 in Q1 2026, 6275000.0 in Q4 2025, and 2530000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Plus Therapeutics | 34.26 Mn | 19.15 Mn | - | -6.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.24 Mn |
| Mar 31, 2026 | -6.24 Mn |
| Dec 31, 2025 | -6.28 Mn |
| Dec 31, 2025 | -6.28 Mn |
| Sep 30, 2025 | -2.53 Mn |
| Sep 30, 2025 | -2.53 Mn |
| Jun 30, 2025 | -5.80 Mn |
| Jun 30, 2025 | -5.80 Mn |
| Mar 31, 2025 | -6.17 Mn |
| Mar 31, 2025 | -6.17 Mn |
| Dec 31, 2024 | -1.21 Mn |
| Dec 31, 2024 | -1.21 Mn |
| Sep 30, 2024 | -3.68 Mn |
| Sep 30, 2024 | -3.68 Mn |
| Jun 30, 2024 | -1.15 Mn |
| Jun 30, 2024 | -1.15 Mn |
| Mar 31, 2024 | -4.51 Mn |
| Mar 31, 2024 | -4.51 Mn |
| Dec 31, 2023 | -1.88 Mn |
| Dec 31, 2023 | -1.88 Mn |